Table 2.
RNA-binding proteins in atherosclerosis-related research.
| RBPs | RNA interactors | Endothelial cells | Smooth muscle cells | Monocyte/macrophages | Atherogenic/atheroprotective | Experimentally validated function | References |
|---|---|---|---|---|---|---|---|
| HUR | LncRNA MAARS/ABCA1 mRNA |
No | No | Yes | Atherogenic | Induce apoptosis and promote cellular cholesterol efflux | (81, 93) |
| STAU1 | LncRNA SMILR | No | Yes | No | Atherogenic | Degrades the SMILR: CENPF interaction to mediate VSMC proliferation | (91) |
| QKI-7 | mRNACD144/ NLGN1/ TSG6 | Yes | No | No | Atherogenic | Defective EC barrier function and compromised angiogenesis | (94) |
| MEX3A | MIR126-5p | Yes | No | No | Atheroprotective | Inhibit proteolytic activity and limit apoptosis | (95) |
| IGF2BP1 | EV-derived miR-146a | No | No | Yes | Atherogenic | Decrease migration and promote macrophage entrapment | (96) |
| EWSR1 | lncRNA RP11-728F11.4 | No | No | Yes | Atherogenic | Increase intracellular cholesterol accumulation and proinflammatory cytokine | (90) |
| LARP6 | COL1a1/COL1a2 mRNA | No | Yes | No | Atherogenic | IGF-1 enhances collagen fibrillogenesis via induction of LARP6 | (97) |
| FUS | lncRNAXXYLT1-AS2 | Yes | No | No | Atheroprotective | Inhibit proliferation and migration | (82) |
| KSRP | miR-185 | No | No | No | Atherogenic | Negatively regulate the expression of LDLR in hepatic cells to control cholesterol homeostasis | (98) |
| VIGILIN | Apolipoprotein B /Apob mRNA | No | No | No | Atherogenic | Increase VLDL/LDL levels and formation of atherosclerotic plaques | (92) |
| ZFP36 | IL-6/MCP-1 mRNA | Yes | No | Yes | Atheroprotective | Regulate MCP-1 and IL-6 mRNA stability and reduce its expression | (99) |
| hnRNPL | linc-AAM | No | No | Yes | Atherogenic | Activate macrophages and promote the immune response | (100) |
| TTP | NLRP3 mRNA | No | No | Yes | Atheroprotective | As a negative regulator of NLRP3 inflammasome | (101) |